Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2020) 70 AEP840 | DOI: 10.1530/endoabs.70.AEP840

ECE2020 Audio ePoster Presentations Reproductive and Developmental Endocrinology (79 abstracts)

Hormonal profile of menopausal women receiving androgen replacement therapy: A meta-analysis

Daniele Santi 1,2 , Giorgia Spaggiari 1 , Antoan S Sojat 3 , Srdjan Pandurevic 3 , Elisa Maseroli 4 & Ljiljana Marina 3

1Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of Modena, Ospedale Civile Baggiovara, Modena, Italy; 2Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy; 3Department of Endocrinology, Clinical Centre of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia; 4Andrology, Women’s Endocrinology and Gender Incongruence Unit, Department of Experimental and Clinical Biomedical Sciences ‘Mario Serio,’ University of Florence, Florence, Italy

Background: Ovarian and adrenal aging leads to a progressive decline in androgens levels and deleterious effects on the quality of life. Despite this, specific hormone replacement is not routinely recommended in the management of women with a physiological or pathological decline in their production, mainly due to the lack of long-term follow-up safety data.

Aim of the study: To evaluate and summarize the existing data about hormonal profile changes in menopausal women receiving androgen replacement treatments, considering all available androgens formulation and regimens.

Methods: The literature search was conducted to identifyall randomized clinical trials and case-control studies evaluating hormonal effects of exogenous administration of any molecule with androgenic action in post-menopausal women published in English language until May 2018 (PROSPERO registration ID: CRD42018099414).

Results: Fifty-threepapers were included in the analysis, accounting for 83 trials. Androgen administration increases testosterone serum levels (2159 treated women vs 2246 controls, P < 0.001), regardless of the molecule used. Similarly, an increase of dehydroepiandrosterone (DHEA) and DHEA-sulfate serum levels was observed (P < 0.001 and P < 0.001, respectively), with a concomitant reduction in sex hormone binding globulin (SHBG) levels (P < 0.001). However, the estrone (E1) and estradiol (E2) increase is evident only when DHEA is administered (P < 0.001 and P < 0.001, respectively), and not when testosterone (P = 0.120 and P = 0.690, respectively) or androstenedione (P = 0.400 and P = 0.540, respectively) where chosen.

Conclusion: Whatever androgen formulation we choose in postmenopausal women, the final result is a rise in testosterone serum levels. However, DHEA regimen shows a combined estrogenic activity. This peculiar action is crucial when choosing the best possible treatment for each patient individually taking into consideration if potential benefits outweigh the risks.

Volume 70

22nd European Congress of Endocrinology

05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.